Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

114 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Corrigendum to: Global Cytopathology-Hematopathology Practice Trends.
Zadeh SL, Balassanian R, Cheung MC, Falchi L, Hasserjian R, Lin O, Long SR, Ly A, Menke JR, Mou E, Natkunam Y, Ruiz-Cordero R, Volaric AK, Wang L, Wen KW, Gratzinger D. Zadeh SL, et al. Among authors: falchi l. Am J Clin Pathol. 2022 Jan 6;157(1):155. doi: 10.1093/ajcp/aqab184. Am J Clin Pathol. 2022. PMID: 34595513 Free PMC article. No abstract available.
Impact of initial biopsy type on the time to final diagnostic biopsy in patients with follicular lymphoma and suspected histologic transformation.
Mou E, Falchi L, Sundaram V, Abramson JS, Balassanian R, Beygi S, Fitzpatrick MJ, Frank AK, Gupta S, Lin O, Reed JR, Long SR, Ly A, Menke JR, Reed DR, Ruiz-Cordero R, Volaric AK, Xie Y, Wang L, Wen KW, Zadeh SL, Natkunam Y, Cheung MC, Gratzinger D; Cyto-Heme Institutional Collaborative (CHIC) consortium. Mou E, et al. Among authors: falchi l. Leuk Lymphoma. 2021 Dec;62(12):2864-2872. doi: 10.1080/10428194.2021.1941936. Epub 2021 Jun 26. Leuk Lymphoma. 2021. PMID: 34176413
Global Cytopathology-Hematopathology Practice Trends.
Zadeh SL, Balassanian R, Cheung MC, Falchi L, Hasserjian R, Lin O, Long SR, Ly A, Menke JR, Mou E, Natkunam Y, Ruiz-Cordero R, Volaric AK, Wang L, Wen KW, Gratzinger D. Zadeh SL, et al. Among authors: falchi l. Am J Clin Pathol. 2022 Feb 3;157(2):196-201. doi: 10.1093/ajcp/aqab111. Am J Clin Pathol. 2022. PMID: 34508545 Free PMC article.
Phase II Trial of Pembrolizumab Plus Gemcitabine, Vinorelbine, and Liposomal Doxorubicin as Second-Line Therapy for Relapsed or Refractory Classical Hodgkin Lymphoma.
Moskowitz AJ, Shah G, Schöder H, Ganesan N, Drill E, Hancock H, Davey T, Perez L, Ryu S, Sohail S, Santarosa A, Galasso N, Neuman R, Liotta B, Blouin W, Kumar A, Lahoud O, Batlevi CL, Hamlin P, Straus DJ, Rodriguez-Rivera I, Owens C, Caron P, Intlekofer AM, Hamilton A, Horwitz SM, Falchi L, Joffe E, Johnson W, Lee C, Palomba ML, Noy A, Matasar MJ, Pongas G, Salles G, Vardhana S, Sanin BW, von Keudell G, Yahalom J, Dogan A, Zelenetz AD, Moskowitz CH. Moskowitz AJ, et al. Among authors: falchi l. J Clin Oncol. 2021 Oct 1;39(28):3109-3117. doi: 10.1200/JCO.21.01056. Epub 2021 Jun 25. J Clin Oncol. 2021. PMID: 34170745 Free PMC article. Clinical Trial.
Adding Umbralisib and Ublituximab (U2) to Ibrutinib in Patients with CLL: A Phase II Study of an MRD-Driven Approach.
Roeker LE, Feldman TA, Soumerai JD, Falco V, Panton G, Dorsey C, Zelenetz AD, Falchi L, Park JH, Straus DJ, Pena Velasquez C, Lebowitz S, Fox Y, Battiato K, Laudati C, Thompson MC, McCarthy E, Kdiry S, Martignetti R, Turpuseema T, Purdom M, Paskalis D, Miskin HP, Sportelli P, Leslie LA, Mato AR. Roeker LE, et al. Among authors: falchi l. Clin Cancer Res. 2022 Sep 15;28(18):3958-3964. doi: 10.1158/1078-0432.CCR-22-0964. Clin Cancer Res. 2022. PMID: 35852793 Free PMC article. Clinical Trial.
Phase II Trial of Nivolumab Plus Doxorubicin, Vinblastine, Dacarbazine as Frontline Therapy in Older Adults With Hodgkin Lymphoma.
Torka P, Feldman T, Savage KJ, Ganesan N, Drill E, Hancock H, Davey T, Perez L, Capadona C, Subzwari S, Galasso N, Yang J, Post M, Boardman A, Caron P, David K, Epstein-Peterson Z, Falchi L, Ghione P, Hamlin P, Horwitz SM, Intlekofer AM, Johnson W, Kumar A, Lue J, Noy A, Owens C, Palomba ML, Salles GA, Steiner R, Stuver R, Vardhana S, Yahalom J, Dogan A, Zelenetz AD, Schöder H, Moskowitz AJ. Torka P, et al. Among authors: falchi l. J Clin Oncol. 2024 Dec 11:JCO2401278. doi: 10.1200/JCO-24-01278. Online ahead of print. J Clin Oncol. 2024. PMID: 39661923
Successful implementation of outpatient R ± DHAX (rituximab, dexamethasone, oxaliplatin, cytarabine) for select patients with lymphoma: a single-center experience.
Pak TK, Dixon BN, Buege MJ, Dao PH, Leary MH, Jarrett JC, Duggan TA, Caron P, Falchi L, Hamlin P, Hamilton A, Matasar MJ, Moskowitz A, Noy A, Owens CN, Von Keudell G, Younes A, Zelenetz AD, Kumar A. Pak TK, et al. Among authors: falchi l. Leuk Lymphoma. 2022 Apr;63(4):876-884. doi: 10.1080/10428194.2021.2002318. Epub 2021 Nov 16. Leuk Lymphoma. 2022. PMID: 34784853
Ofatumumab and Lenalidomide for Patients with Relapsed or Refractory Chronic Lymphocytic Leukemia: Correlation between Responses and Immune Characteristics.
Vitale C, Falchi L, Ten Hacken E, Gao H, Shaim H, Van Roosbroeck K, Calin G, O'Brien S, Faderl S, Wang X, Wierda WG, Rezvani K, Reuben JM, Burger JA, Keating MJ, Ferrajoli A. Vitale C, et al. Among authors: falchi l. Clin Cancer Res. 2016 May 15;22(10):2359-67. doi: 10.1158/1078-0432.CCR-15-2476. Epub 2016 Jan 5. Clin Cancer Res. 2016. PMID: 26733610 Free PMC article. Clinical Trial.
114 results